Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02255266 |
Recruitment Status :
Completed
First Posted : October 2, 2014
Last Update Posted : April 17, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Diabetes Diabetes Mellitus, Type 2 | Drug: liraglutide |
Study Type : | Observational |
Actual Enrollment : | 1788 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice |
Actual Study Start Date : | March 26, 2015 |
Actual Primary Completion Date : | November 16, 2015 |
Actual Study Completion Date : | November 16, 2015 |

Group/Cohort | Intervention/treatment |
---|---|
A |
Drug: liraglutide
No treatment given. |
- Frequency of patients achieving HbA1c reduction of at least 1%-point [ Time Frame: Week 0, week 52 ]
- Change in HbA1c (Glycosylated haemoglobin)) [ Time Frame: Week 0, week 104 ]
- Change in body weight [ Time Frame: Week 0, week 104 ]
- Frequency of patients achieving HbA1c reduction of at least 1%-point [ Time Frame: After 4 and 24 months of treatment ]
- Frequency of patients achieving HbA1c target (<=7%) [ Time Frame: After 4, 12 and 24 months ]
- Frequency of patients achieving a body weight reduction of at least 3% [ Time Frame: After 4, 12 and 24 months ]
- Frequency of patients achieving the composite endpoint consisting in: HbA1c reduction of at least 1%-point and body weight reduction of at least 3% [ Time Frame: After 4, 12 and 24 months ]
- Percentage of treatment discontinuation for any reason [ Time Frame: At 4, 12 and 24 months ]
- Changes in blood pressure and lipid profile [ Time Frame: Week 0, week 104 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Subjects of age above 18 years as per Victoza® SmPC par.4.2 and 5.1 diagnosed with type 2 diabetes receiving the first prescription of liraglutide in 2011
Exclusion Criteria:
- None. Available data from all eligible patients for each center, will be included

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02255266
Italy | |
Novo Nordisk Investigational Site | |
Rome, Italy, 00144 |
Study Director: | Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S |
Publications of Results:
Responsible Party: | Novo Nordisk A/S |
ClinicalTrials.gov Identifier: | NCT02255266 |
Other Study ID Numbers: |
NN2211-4118 U1111-1143-9842 ( Other Identifier: WHO ) |
First Posted: | October 2, 2014 Key Record Dates |
Last Update Posted: | April 17, 2018 |
Last Verified: | April 2018 |
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Liraglutide |
Hypoglycemic Agents Physiological Effects of Drugs Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |